Dr. Peter Kador is the Founder, President, and CEO, and an internationally recognized expert in ocular pharmacology, medicinal chemistry, and cataract research. His career spans government, academia, and translational drug development, with a sustained focus on therapies for diabetic and age-related eye diseases. Dr. Kador spent 25 years at the National Eye Institute at the National Institutes of Health, where he retired as Chief of the Laboratory of Ocular Therapeutics. His research centered on the development of pharmacologic agents targeting aldose reductase and other key pathways involved in diabetic complications, including cataract and retinopathy. He was subsequently recruited to the University of Nebraska Medical Center as Professor and Chair of Pharmaceutical Sciences and Professor of Ophthalmology, where he now holds Emeritus status. His work has played a significant role in advancing the scientific foundation for therapies aimed at preventing vision loss and treating ocular complications of diabetes. Dr. Kador has held numerous leadership roles in vision research organizations and has received multiple international awards recognizing his contributions to the field. As both a scientist and entrepreneur, he has successfully translated fundamental biochemical discoveries into therapeutic strategies, positioning the company at the forefront of preventive treatments for ocular disease.